Condition: Gastric Adenocarcinoma · Gastric (Stomach) Cancer · GEJ Adenocarcinoma · Sponsor: Henan Cancer Hospital
This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
This description comes directly from the study's public registry record.
Huifang Lv · 8618639027635 · zlyylvhf1859@zzu.edu.cn
Always discuss trial participation with your own doctor first.
| Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University) | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07334431